Fasting plasma triglycerides predict the glycaemic response to treatment of Type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm

Diabetic Medicine

Volumn 30, Issue 6, 2013, Pages 687-693

  Lebovitz, H E ^a   Ludvik, B ^b   Yaniv, I ^c   Haddad, W ^c   Schwartz, T ^c   Aviv, R ^d  

^a Downstate Health Sciences University   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Metacure Research   (Israel)

^d Metacure Research   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ELECTROSTIMULATION THERAPY; FOLLOW UP; GASTRIC ELECTRICAL STIMULATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPOTOXICITY; MEDICAL DEVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; STOMACH MUSCLE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; IMPLANTS, EXPERIMENTAL; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MUSCLE CONTRACTION; OBESITY; STOMACH; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84878094706     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12132     Document Type: Article

References (28)

1. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393-411.
2. ® system in obese type 2 diabetic patients: effect on weight and glycemic control. J Diabetes Sci Technol 2009; 3: 964-970.
3. Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Therap 2009; 11: 725-732.
4. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with Type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479-2485.
5. Harvey EJ, Arroyo K, Korner J, Inabnet WB. Hormone changes affecting energy homeostasis after metabolic surgery. Mt Sinai J Med 2010; 77: 446-465.
6. Thaler JP, Cummings DE. Food alert. Nature 2008; 452: 941-942.
7. Greenway F, Zheng J. Electrical stimulation as treatment for obesity and diabetes. J Diabetes Sci Technol 2007; 1: 251-259.
8. Policker S, Haddad W, Yaniv I. Treatmentof type 2 diabetes using meal-triggered gastric electrical stimulation. Isr Med Assoc J 2009; 11: 206-208.
9. TM) in overweight subjects with type 2 diabetes. Surg Endosc 2009; 23: 1955-1960.
10. Wallace TM, Levy JC, Matthews DE. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
11. Jackson SL. Research Methods and Statistics: A Critical Thinking Approach. 4th edition. Belmont, CA: Publisher Wadsworth, 2011.
12. Ravikumar B, Gerrard J, Man CD, Firbank MJ, Lane A, English PT et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008; 57: 2288-2295.
13. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride contentin obese subjects. Gastroenterology 2008; 134: 1369-1375.
14. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010; 21: 345-352.
15. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-1192.
16. Adams JM II, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53: 25-31.
17. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55: S9-S15.
18. Consitt LA, Bell JA, Houmard JA. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life 2009; 61: 47-55.
19. Gallagher EJ, LeRoith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai j Med 2010; 77: 511-523.
20. Van Raalte DH, van der Zijl NJ, Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity. Curr Opin Clin Nutr Metab Care 2010; 13: 478-485.
21. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effect on human pancreatic islets. Diabetes 2002; 51: 1437-1442.
22. Magnan C, Cruciani C, Clement L, Adnot P, Vincent M, Kergoat M et al. Glucose-induced insulin hypersecretion in lipid infused healthy subjects is associated with a decrease in plasma norepinephrine concentration and urinary excretion. J Clin Endocrinol Metab 2001; 86: 4901-4907.
23. Carpentier A, Mittleman SD, Bergman RN, Giacca A, Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic β-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000; 49: 399-408.
24. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
25. Wang PYT, Caspi L, Lam CKL, Chari M, Li X, Light PE et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 2008; 452: 1012-1016.
26. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 2005; 1: 53-61.
27. ATP channels control hepatic glucose production. Nature 2005; 434: 1028-1031.
28. Leitao CB, Bernetti K, Tharavanij T, Cure P, Lauriola V, Berggren P-O et al. Lipotoxicity and decreased islet graft survival. Diabetes Care 2010; 33: 658-660.